2012 European guideline on the diagnosis and treatment of gonorrhoea in adults
2012 European guideline on the diagnosis and treatment of gonorrhoea in adults
复制标题
DOI：
10.1177/0956462412472837
复制
发表时间：
2013-02-01
影响因子：
1.4
通讯作者：
Unemo, M.
中科院分区：
文献类型：
--
作者：
Bignell, C.;Unemo, M.
淋病是全球主要的公共卫生问题。特别令人严重关切的是，最近几年出现了对广谱头孢菌素的耐药性。该指南提供了关于欧洲淋病诊断和治疗的建议。与过时的2009年欧洲淋病指南相比，2012年欧洲淋病指南提供了最新的指导，更广泛的淋病检测和治疗适应症;双重抗菌治疗的引入（头孢曲松500 mg和阿奇霉素2 g）用于抗生素敏感性未知的无并发症淋病;建议在所有淋病病例中进行治愈测试，以确保根除感染并确定新出现的耐药性;并建议确定、核实和报告推荐治疗方案的失败情况。优化淋病患者的检测、诊断、抗菌治疗和随访对于控制头孢菌素耐药和多重耐药淋病的紧急传播至关重要。
Gonorrhoea is a major public health concern globally. Of particularly grave concern is that resistance to the extended-spectrum cephalosporins has emerged during the most recent years. This guideline provides recommendations regarding the diagnosis and treatment of gonorrhoea in Europe. Compared to the outdated 2009 European gonorrhoea guideline, this 2012 European gonorrhoea guideline provides up-to-date guidance on, broader indications for testing and treatment of gonorrhoea; the introduction of dual antimicrobial therapy (ceftriaxone 500 mg and azithromycin 2 g) for uncomplicated gonorrhoea when the antimicrobial sensitivity is unknown; recommendation of test of cure in all gonorrhoea cases to ensure eradication of infection and identify emerging resistance; and recommendations to identify, verify and report failures with recommended treatment regimens. Optimisations of the testing, diagnostics, antimicrobial treatment and follow-up of gonorrhoea patients are crucial in controlling the emergent spread of cephalosporin-resistant and multidrug-resistant gonorrhoea.